Evidence map›Paper›PMID 35740525›Full record

ArticleCancers2022

Zeenat Jahan, Fahad A Benthani, Nicola Currey, Hannah W Parker, Jane E Dahlstrom, C Elizabeth Caldon, Maija R J Kohonen-Corish

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Zeenat JahanWoolcock Institute of Medical Research, 431 Glebe Point Road, Glebe, Sydney, NSW 2037, Australia.
Fahad A BenthaniGarvan Institute of Medical Research, Sydney, NSW 2010, Australia.ORCID 0000-0002-3283-307X
Nicola CurreyGarvan Institute of Medical Research, Sydney, NSW 2010, Australia.
Hannah W ParkerWoolcock Institute of Medical Research, 431 Glebe Point Road, Glebe, Sydney, NSW 2037, Australia.ORCID 0000-0002-4645-6252
Jane E DahlstromACT Pathology, The Canberra Hospital and Australian National University Medical School, Canberra, ACT 2605, Australia.ORCID 0000-0001-5608-693X
C Elizabeth CaldonGarvan Institute of Medical Research, Sydney, NSW 2010, Australia.ORCID 0000-0003-1392-3472
Maija R J Kohonen-CorishWoolcock Institute of Medical Research, 431 Glebe Point Road, Glebe, Sydney, NSW 2037, Australia.
Garvan Institute of Medical Research · AUUniversity of Technology Sydney · AUAustralian National University · AU

Funding

Cancer Council New South Wales 17-05 and 19-01Gastroenterological Society of Australia GESA 2017Sydney Catalyst FB
6 · The paper itself

Abstract

Chemotherapy is a mainstay of colorectal cancer treatment, and often involves a combination drug regime. CpG island methylator phenotype (CIMP)-positive tumors are potentially more responsive to the topoisomerase-inhibitor irinotecan. The mechanistic basis of the increased sensitivity of CIMP cancers to irinotecan is poorly understood. Mutated in Colorectal Cancer (

Indexed as

CIMPcolorectal cancerepigenetic biomarkermutated in colorectal cancer (MCC)precision medicine

Identifiers

PMID35740525
PMCPMC9221012
OpenAlexW4281646280

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.